ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,101.24
-0.29%
US Tech 100
21,156.80
-0.70%
다우존스 지수
44,424.25
-0.32%
Bitcoin
104,811.18
0.08%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Precision BioSciences Inc (DTIL)

  7. Precision BioSciences Inc (DTIL) 뉴스

DTIL

Precision BioSciences (DTIL)

Precision BioSciences Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:DTIL
일자시간출처헤드라인심볼기업
2025/01/2505:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2305:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2305:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2206:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/1000:01Business WirePrecision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
2025/01/0922:00Business WireiECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
2025/01/0822:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
2025/01/0221:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/3121:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/3121:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/3020:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/1821:01Business WirePrecision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
2024/11/2206:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/2121:01Business WirePrecision BioSciences to Participate in Upcoming November Investor ConferencesNASDAQ:DTILPrecision BioSciences Inc
2024/11/1521:00Business WirePrecision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
2024/11/0609:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0609:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0609:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0505:51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0505:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0421:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DTILPrecision BioSciences Inc
2024/11/0421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
2024/11/0421:01Business WirePrecision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
2024/10/2920:01Business WirePrecision BioSciences to Report Third Quarter Results on November 4, 2024NASDAQ:DTILPrecision BioSciences Inc
2024/10/2820:01Business WirePrecision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024NASDAQ:DTILPrecision BioSciences Inc
2024/10/2505:15Business WirePrecision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual CongressNASDAQ:DTILPrecision BioSciences Inc
 검색 관련기사 보기:NASDAQ:DTIL

최근 히스토리

BIT
I06603
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유